Die Rolle der Glykogen Synthase Kinase 3β in der Regulation von DNS-Schäden und Chemotherapieresistenz im Pankreaskarzinom

by Anna Eleonora Angelika Tirilomi-Mascher née Tirilomi
Doctoral thesis
Date of Examination:2024-09-25
Date of issue:2024-09-24
Advisor:Prof. Dr. Volker Ellenrieder
Referee:Prof. Dr. Volker Ellenrieder
Referee:Prof. Dr. Philipp Ströbel
Persistent Address: http://dx.doi.org/10.53846/goediss-10754

 

 

Files in this item

Name:Dissertation Anna Tirilomi-Mascher_ediss.pdf
Size:2.84Mb
Format:PDF

The following license files are associated with this item:

Abstract

English

Pancreatic carcinoma is one of the most aggressive solid tumour types and is characterized by pronounced molecular heterogeneity. Research is continuing into molecularly definable subgroups that are suitable for targeted, individualized treatment. In particularly aggressive subgroups of pancreatic cancer, glycogen synthase kinase 3β (GSK3β) has been identified, which is associated with tumor cell proliferation, de-differentiation, progression and resistance to chemotherapy. An oncogenic effect of GSK3β has been demonstrated in multiple tumor entities. Using established murine and human cell lines as well as primary cell lines isolated from PDX tumors (patient-derived xenografts), the role of glycogen synthase kinase 3β in the regulation of DNA damage was investigated.
Keywords: pancreatic cancer; GSK3β; chemotherapy; chemotherapy resistance
Schlagwörter: Pankreaskarzinom; GSK3β; Chemotherapie; Chemotherapieresistenz
 
Statistik